Literature DB >> 22825233

Evaluation of outcomes of a medication therapy management program for patients with diabetes.

Sharrel L Pinto1, Robert A Bechtol, Gautam Partha.   

Abstract

OBJECTIVE: To measure the impact of an employer-sponsored, pharmacist-provided medication therapy management (MTM) program on clinical outcomes and social and process measures for patients with diabetes with or without associated comorbid conditions.
METHODS: Prospective longitudinal study that took place at seven independent pharmacies in Lucas County, OH. A total of 228 patients with diabetes were enrolled. At 6-month intervals, patients were counseled by their pharmacists. Outcome measures included clinical outcomes (glycosylated hemoglobin [A1C], systolic blood pressure (SBP), and diastolic blood pressure [DBP]), social measures (caffeine intake, alcohol consumption, smoking, and exercise), and process measures (visits to ophthalmologist, podiatrist, and dentist). Wilcoxon signed-rank test and percentages were used to report findings.
RESULTS: Mean (± SD) A1C concentration decreased from 7.08 ± 1.54% to 6.89 ± 1.30% at 12 months. Patients with A1C levels greater than 7% at baseline averaged a decrease of 0.5% at 6 months and 0.75% at 12 months. Mean SBP values decreased significantly from baseline to 12 months. A total of 87 patients with a baseline SBP greater than 130 mm Hg experienced a significant change in blood pressure from baseline to 6 months (-7.1 ± 3.32 mm Hg), and 65 patients experienced a significant change in blood pressure from baseline to 12 months (-11.49 ± 0.15 mm Hg). A total of 104 patients with a baseline DBP more than 80 mm Hg experienced a significant decrease of 4.44 ± 1.25 mm Hg at 6 months. Caffeine and alcohol consumption and smoking decreased and exercise increased. In addition, the percentage of patients who visited specialists increased.
CONCLUSION: Patients with diabetes experienced improvements in multiple clinical, social, and process measures.

Entities:  

Mesh:

Year:  2012        PMID: 22825233     DOI: 10.1331/JAPhA.2012.10098

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  7 in total

1.  Impact of pharmacist-led care on glycaemic control of patients with uncontrolled type 2 diabetes: a randomised controlled trial in Nigeria.

Authors:  Emmanuel A David; Rebecca O Soremekun; Isaac O Abah; Roseline I Aderemi-Williams
Journal:  Pharm Pract (Granada)       Date:  2021-08-14

Review 2.  A review of advances in collaborative pharmacy practice to improve adherence to standards of care in diabetes management.

Authors:  Michael P Conley; Christine Chim; Chelsea E Magee; Daniel J Sullivan
Journal:  Curr Diab Rep       Date:  2014-03       Impact factor: 4.810

Review 3.  Systematic review of community pharmacy-based and pharmacist-led foot care interventions for adults with type 2 diabetes.

Authors:  Allison L Soprovich; Vishal Sharma; Lisa Tjosvold; Dean T Eurich; Jeffrey A Johnson
Journal:  Can Pharm J (Ott)       Date:  2019-02-15

Review 4.  The role of the pharmacist in the management of type 2 diabetes: current insights and future directions.

Authors:  Jeffery David Hughes; Yosi Wibowo; Bruce Sunderland; Kreshnik Hoti
Journal:  Integr Pharm Res Pract       Date:  2017-01-16

5.  Community Pharmacist-Provided Wellness and Monitoring Services in an Employee Wellness Program: A Four-Year Summary.

Authors:  Yifei Liu; Kendall D Guthrie; Justin R May; Kristen L DiDonato
Journal:  Pharmacy (Basel)       Date:  2019-07-02

6.  Clinical and humanistic impact of pharmacotherapeutic follow-up in patients with type 1 diabetes mellitus treated judicially.

Authors:  Thays S Mendonça; William N Oliveira; Vinícius S Belo; Eduardo S Silva; Mariana L Pereira; Paulo R Obreli-Neto; André O Baldoni
Journal:  Diabetol Metab Syndr       Date:  2022-05-03       Impact factor: 5.395

Review 7.  An evolving role of clinical pharmacists in managing diabetes: Evidence from the literature.

Authors:  Samia Alhabib; Maha Aldraimly; Ali Alfarhan
Journal:  Saudi Pharm J       Date:  2014-08-07       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.